Clinical Scenario: Treating Late-Line Relapsed Multiple Myeloma

News
Video

Following the repeat diagnostic workup presentation, an expert will lead the discussion, inviting the panel's input on the most appropriate treatment course for this patient.

Newsletter

Stay up to date on recent advances in oncology nursing and patient care.

Subscribe Now!
Recent Videos
Image of a woman wearing a patterned shirt in front of a dark blue background
Photo of a woman wearing a blazer in front of an Oncology Nursing News backdrop
Photo of a woman with dark curly hair wearing a floral shirt
Image of a woman with gray hair on a light blue background
Photo of a woman with a blue border around the image
Image of a woman with dark hair wearing a floral shirt in front of a blurred background
Screenshot of Kiah Purcell, MSN, AGPCNP-BC, in a video call with the frame surrounded by an Oncology Nursing News branded border
Related Content
Graphic of myeloma cells

Q&A: Transitioning Myeloma Care to the Community Level

Bridget Hoyt
June 27th 2025
Article

Formal communication could help ease the transition of care from specialized myeloma centers to community clinic, according to Diane Moran, RN, MA, EdM.

The Vitals

Finley-Oliver Talks Talquetamab and Other Later Line Multiple Myeloma Therapies

Lindsay Fischer
December 14th 2023
Podcast

Beth Finley-Oliver, MSN, ARNP, AGNP-BC, recaps part of her presentation from the 2023 JADPRO meeting about caring for patients with high-risk multiple myeloma.

Illustration of two medical workers holding up a magnifying glass to a cross-section of a bone

Subcutaneous Daratumumab Could Mark First Smoldering Myeloma Treatment

Bridget Hoyt
June 21st 2025
Article

Per ODAC and CHMP recommendations, subcutaneous daratumumab may become the first approved treatment for smoldering myeloma. Here’s what nurses should know.

Beth Faiman Discusses Recent Changes in Multiple Myeloma Treatment Landscape

Beth Faiman Discusses Recent Changes in Multiple Myeloma Treatment Landscape

Lindsay Fischer
April 13th 2023
Podcast

Beth Faiman, PhD, CNP, discusses reclassifying patients with multiple myeloma, the accelerated approval of teclistamab, and the removal of belantamab mafodotin from the US market.

Image of red blood cells

Allogeneic CT0596 Shows Early Activity, Safety in R/R Myeloma

Chris Ryan
May 20th 2025
Article

CT0596 was well tolerated and showed preliminary efficacy in relapsed/refractory multiple myeloma, early phase 1 data show.

PDF of Rx Road Map for subcutaneous daratumumab in multiple myeloma

Rx Road Map: Subcutaneous Daratumumab in Multiple Myeloma

Sylwia Zielinska, RN
Published: May 7th 2025 | Updated: June 5th 2025
Article

A registered nurse gives best practices for use of subcutaneous daratumumab in multiple myeloma.